Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Synalgos
Overview
What is Synalgos?
Each Synalgos-DC capsule contains 16 mg drocode (dihydrocodeine) bitartrate (Warning–may be habit-forming), 356.4 mg aspirin, and 30 mg caffeine.
The inactive ingredients present are alginic acid, cellulose, D&C Red 28, FD&C Blue 1, gelatin, iron oxides, stearic acid, and titanium dioxide.
What does Synalgos look like?
What are the available doses of Synalgos?
Sorry No records found.
What should I talk to my health care provider before I take Synalgos?
Sorry No records found
How should I use Synalgos?
Dosage should be adjusted according to the severity of the pain and the response of the patient. Synalgos-DC is given orally. The usual adult dose is two capsules every 4 hours as needed for pain.
What interacts with Synalgos?
Synalgos-DC is contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy.
Synalgos-DC is contraindicated in patients with hypersensitivity to dihydrocodeine, codeine, or aspirin
What are the warnings of Synalgos?
Withdrawal symptoms (of the barbiturate type) have occurred after the abrupt discontinuation of benzodiazepines (see ).
Death Related to Ultra-Rapid Metabolism of Codeine to Morphine
Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine.
Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert dihydrocodeine into its active metabolite, dihydromorphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum dihydromorphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing).
Children with obstructive sleep apnea who are treated with codeine for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Synalgos-DC is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy [see Contraindications].
When prescribing dihydrocodeine-containing drugs, healthcare providers should choose the lowest effective dose for the shortest period of time and inform patients and caregivers about these risks and the signs of dihydromorphine overdose.
Drug Dependence
Dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of dihydrocodeine, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic-containing medications. Like other narcotic-containing medications, dihydrocodeine is subject to the provisions of the Federal Controlled Substances Act.
Usage in Ambulatory Patients
Dihydrocodeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. The patient using Synalgos-DC should be cautioned accordingly.
Interactions with other Central Nervous System Depressants
Patients receiving other narcotic analgesics, general anesthetics, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) concomitantly with Synalgos-DC may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.
Usage in Pregnancy
Reproduction studies have not been performed in animals. There is no adequate information on whether this drug may affect fertility in human males and females or has a teratogenic potential or other adverse effect on the fetus.
Usage in Nursing Mothers
Dihydrocodeine bitartrate is secreted into human milk. In women with normal dihydrocodeine metabolism (normal CYP2D6 activity), the amount of dihydrocodeine secreted into human milk is low and dosedependent. However, some women are ultra-rapid metabolizers of dihydrocodeine. These women achieve higher-than-expected serum levels of dihydrocodeine’s active metabolite, dihydromorphine, leading to higher-than-expected levels of dihydromorphine in breast milk and potentially dangerously high serum dihydromorphine levels in their breastfed infants. Therefore, maternal use of dihydrocodeine can potentially lead to serious adverse reactions, including death, in nursing infants.
The risk of infant exposure to dihydrocodeine and dihydromorphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the baby. Caution should be exercised when dihydrocodeine is administered to a nursing woman. If a dihydrocodeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using dihydrocodeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of dihydrocodeine during breast-feeding [see Warnings].
Aspirin and caffeine are also excreted in breast milk in small amounts. Because of the potential for serious adverse reactions in nursing infants from this combination product, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Usage in Children
Preparations containing aspirin should be kept out of the reach of children. Synalgos-DC is not recommended for patients 12 years of age and under. Since there is no experience in children who have received this drug, safety and efficacy in children have not been established.
Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Synalgos-DC is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy [see Contraindications].
What are the precautions of Synalgos?
Synalgos-DC should be given with caution to certain patients, such as the elderly or debilitated.
Information for Patients
Advise patients that some people have a genetic variation that results in dihydrocodeine changing into dihydromorphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid dihydrocodeine metabolizer or not. These higher-than-normal levels of dihydromorphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression. Synalgos- DC is contraindicated in all children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving Synalgos-DC for other reasons to monitor for signs of respiratory depression.
Advise patients that nursing mothers taking dihydrocodeine can have higher dihydromorphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of dihydromorphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Advise nursing mothers to watch for signs of dihydromorphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby’s doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).
Drug Interactions
The CNS-depressant effects of Synalgos-DC may be additive with that of other CNS depressants. See “.”
Aspirin may enhance the effects of anticoagulants and inhibit the uricosuric effects of uricosuric agents.
Geriatric Use
Clinical studies of Synalgos-DC did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects.
In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
What are the side effects of Synalgos?
The most frequently observed reactions include lightheadedness, dizziness, drowsiness, sedation, nausea, vomiting, constipation, pruritus, and skin reactions.
What should I look out for while using Synalgos?
W
What might happen if I take too much Synalgos?
Sorry No Records found
How should I store and handle Synalgos?
Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature).Protect from freezing and excessive heat.Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature).Protect from freezing and excessive heat.Synalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.comSynalgos-DC Capsules are blue and gray, marked “CP” and “419”, supplied in:Bottles of 100 capsules; NDC 49708-419-88Store at room temperature, approx. 25°C (77°F). Keep tightly closed.Dispense in tight container.Manufactured by: C.S. No.:8002T02Mikart, Inc. Rev. 02/13Atlanta, Georgia 30318 Code 990B00 Distributed by:Caraco Pharmaceutical Laboratories, Ltd.1150 Elijah McCoy DriveDetroit, MI 48202www.caraco.com
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Non-Clinical Toxicology
WReference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).